RAFAEL HOLDINGS INC-CLASS B (RFL) Stock News
NYSE:RFL - New York Stock Exchange, Inc. - US75062E1064 - Common Stock - Currency: USD
RFL Latest News, Press Relases and Analysis
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic...
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
Mentions: CYTH
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
Mentions: CYTH
RFL Stock Earnings: Rafael Holdings Reported Results for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rafael Holdings (NYSE:RFL) just reported results for the third quarter of 2024....
RFL Stock Earnings: Rafael Holdings Reported Results for Q3 2024
Rafael Holdings just reported results for the third quarter of 2024.
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rafael Holdings (NYSE:RFL) just reported results for the first quarter of 2024....
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its...
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™...
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™
Mentions: CYTH
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high...
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need
Mentions: CYTH
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
Rafael Holdings just reported results for the first quarter of 2024.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHEB, ARC, RFL on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: ARC
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
RFL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic...
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
Mentions: CYTH
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Mentions: CYTH
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive...
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
Mentions: CYTH
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
Mentions: CYTH
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Mentions: CYTH
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments ...
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments...
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments
Mentions: CYTH
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Mentions: CYTH
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities...
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities
Mentions: CYTH
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
Mentions: CYTH